 | Up a level |
Cappellini, M. D. and Viprakasit, V. and Taher, A. T. and Georgiev, P. and Kuo, K. H. M. and Coates, T. and Voskaridou, E. and Liew, H. -K. and Pazgal-Kobrowski, I. and Forni, G. L. and Perrotta, S. and Khelif, A. and Lal, A. and Kattamis, A. and Vlachaki, E. and Origa, R. and Aydinok, Y. and Bejaoui, M. and Ho, P. J. and Chew, L. -P. and Bee, P. -C. and Lim, S. -M. and Lu, M. -Y. and Tantiworawit, A. and Ganeva, P. and Gercheva, L. and Shah, F. and Neufeld, E. J. and Thompson, A. and Laadem, A. and Shetty, J. K. and Zou, J. and Zhang, J. and Miteva, D. and Zinger, T. and Linde, P. G. and Sherman, M. L. and Hermine, O. and Porter, J. and Piga, A. and Investigators, BELIEVE (2020) A phase 3 trial of Luspatercept in patients with transfusion-dependent beta-thalassemia. New England Journal of Medicine, 382 (13). pp. 1219-1231. ISSN 0028-4793, DOI https://doi.org/10.1056/NEJMoa1910182.
Pennell, D. and Porter, J.B. and Cappellini, M.D. and Chan, L.L. and El-Beshlawy, A. and Aydinok, Y. and Ibrahim, H. and Li, Chi-Kong and Viprakasit, V. and Elalfy, M.S. and Kattamis, A. and Smith, G. and Habr, D. and Domokos, G. and Roubert, B. and Taher, A. (2010) Continued improvement and normalization of myocardial T2*in patients with beta-thalassemia major treated with deferasirox (Exjade (R)) for up to 3 years. Blood, 116 (21). pp. 1735-1736.
Pennell, D. and Porter, J. and Cappellini, M. and Chan, L.L. and El-Beshlawy, A. and Aydinok, Y. and Ibrahim, H. and Li, C.K. and Viprakasit, V. and Elalfy, M. and Kattamis, A. and Smith, G. and Habr, D. and Roubert, B. and Taher, A. (2010) Continued improvement in cardiac T2*with deferasirox treatment over 2 years: Results from the extension of epic cardiac substudy in beta-thalassaemia patients with myocardial siderosis. Haematologica-The Hematology Journal, 95 (2). pp. 202-203.
Pennell, D. and Porter, J. and Cappellini, M. and Chan, L.L. and El-Beshlawy, A. and Aydinok, Y. and Ibrahim, H. and Li, C.K. and Viprakasit, V. and Elalfy, M. and Kattamis, A. and Smith, G. and Habr, D. and Roubert, B. and Taher, A. (2010) Deferasirox effectively removes cardiac iron in beta-thalassaemia patients with myocardial siderosis previously chelated with deferoxamine monotherapy or deferoxamine-deferiprone therapy. Haematologica-The Hematology Journal, 95 (2). p. 699.
Pennell, D.J. and Porter, J.B. and Cappellini, M.D. and El-Beshlawy, A. and Chan, L.L. and Aydinok, Y. and Elalfy, M.S. and Sutcharitchan, P. and Li, C.K. and Ibrahim, H. and Viprakasit, V. and Kattamis, A. and Smith, G. and Habr, D. and Domokos, G. and Roubert, B. and Taher, A. (2010) Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood, 115 (12). pp. 2364-2371.
Cappellini, M.D. and Porter, J. and El-Beshlawy, A. and Li, C.K. and Seymour, J.F. and Elalfy, M. and Gattermann, N. and Giraudier, S. and Lee, J.W. and Chan, L.L. and Lin, K.H. and Rose, C. and Taher, A. and Thein, S.L. and Viprakasit, V. and Habr, D. and Domokos, G. and Roubert, B. and Kattamis, A. and Investigators, EPIC Study (2010) Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica-The Hematology Journal, 95 (4). pp. 557-566.
